- Home
- PBYI vs DLNG Comparison
PBYI vs DLNG Comparison
Compare PBYI & DLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- DLNG
- Stock Information
- Founded
- PBYI 2010
- DLNG 2013
- Country
- PBYI United States
- DLNG Greece
- Employees
- PBYI N/A
- DLNG N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- DLNG Marine Transportation
- Sector
- PBYI Health Care
- DLNG Consumer Discretionary
- Exchange
- PBYI Nasdaq
- DLNG Nasdaq
- Market Cap
- PBYI 145.3M
- DLNG 157.7M
- IPO Year
- PBYI N/A
- DLNG 2013
- Fundamental
- Price
- PBYI $2.91
- DLNG $4.14
- Analyst Decision
- PBYI Strong Buy
- DLNG
- Analyst Count
- PBYI 1
- DLNG 0
- Target Price
- PBYI $7.00
- DLNG N/A
- AVG Volume (30 Days)
- PBYI 288.9K
- DLNG 87.9K
- Earning Date
- PBYI 02-27-2025
- DLNG 03-26-2025
- Dividend Yield
- PBYI N/A
- DLNG 2.36%
- EPS Growth
- PBYI 492.79
- DLNG 42.98
- EPS
- PBYI 0.47
- DLNG 0.99
- Revenue
- PBYI $243,569,000.00
- DLNG $151,689,000.00
- Revenue This Year
- PBYI N/A
- DLNG N/A
- Revenue Next Year
- PBYI N/A
- DLNG N/A
- P/E Ratio
- PBYI $6.24
- DLNG $4.27
- Revenue Growth
- PBYI 6.30
- DLNG N/A
- 52 Week Low
- PBYI $2.23
- DLNG $2.27
- 52 Week High
- PBYI $7.15
- DLNG $5.65
- Technical
- Relative Strength Index (RSI)
- PBYI 48.76
- DLNG 28.85
- Support Level
- PBYI $2.69
- DLNG $4.21
- Resistance Level
- PBYI $2.98
- DLNG $4.40
- Average True Range (ATR)
- PBYI 0.12
- DLNG 0.23
- MACD
- PBYI 0.01
- DLNG -0.04
- Stochastic Oscillator
- PBYI 58.11
- DLNG 4.44
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About DLNG Dynagas LNG Partners LP Common Units
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.